Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Stock Has Consensus Target Price of $10.00

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) has been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $10.00.

Several analysts have recently weighed in on ATHE shares. JonesTrading began coverage on shares of Alterity Therapeutics in a research report on Tuesday, June 30th. They set a “buy” rating and a $16.00 price objective on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Alterity Therapeutics in a research note on Friday, July 17th. UBS Group set a $12.00 price target on Alterity Therapeutics in a research note on Tuesday, August 11th. LADENBURG THALM/SH SH started coverage on Alterity Therapeutics in a report on Tuesday, June 16th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, Lake Street Capital initiated coverage on Alterity Therapeutics in a research report on Tuesday, September 15th. They set a “buy” rating and a $10.00 price objective on the stock.

Institutional Investors Weigh In On Alterity Therapeutics

A hedge fund recently raised its position in Alterity Therapeutics stock. Greenleaf Trust boosted its holdings in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) by 93.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 62,000 shares of the company’s stock after purchasing an additional 30,000 shares during the period. Greenleaf Trust owned approximately 0.70% of Alterity Therapeutics worth $333,000 at the end of the most recent reporting period. 2.14% of the stock is currently owned by institutional investors.

Alterity Therapeutics Price Performance

Shares of NASDAQ ATHE opened at $3.37 on Wednesday. The business has a 50-day moving average of $4.23 and a 200-day moving average of $4.34. Alterity Therapeutics has a 12 month low of $2.66 and a 12 month high of $5.89.

Alterity Therapeutics (NASDAQ:ATHE) last announced its earnings results on Thursday, July 30th. The company reported ($0.28) earnings per share (EPS) for the quarter. The business had revenue of $0.31 million for the quarter. Analysts predict that Alterity Therapeutics will post -0.12 earnings per share for the current fiscal year.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited (NASDAQ: ATHE) is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company’s research centers on protein misfolding and aggregation, biological processes associated with conditions such as multiple system atrophy (MSA) and Parkinson’s disease.

Alterity’s lead drug candidate is ATH434, an orally administered small molecule designed to inhibit the aggregation of alpha-synuclein, a protein implicated in several neurodegenerative disorders.